Renal cell carcinoma 4

Common Name(s)

Renal cell carcinoma 4

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Renal cell carcinoma 4" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Renal cell carcinoma 4" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Renal cell carcinoma 4" returned 49 free, full-text research articles on human participants. First 3 results:

Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
 

Author(s): Xiezhao Li, Peng Xu, Chongshan Wang, Naijin Xu, Abai Xu, Yawen Xu, Takuya Sadahira, Motoo Araki, Koichiro Wada, Eiji Matsuura, Masami Watanabe, Junxia Zheng, Pinghua Sun, Peng Huang, Yasutomo Nasu, Chunxiao Liu

Journal: Oncotarget. 2017 Mar;8(13):21177-21186.

 

Renal cell carcinoma (RCC) management has undergone a major transformation over the past decade; immune checkpoint inhibitors are currently undergoing clinical trials and show promising results. However, the effectiveness of immune checkpoint inhibitors in patients with metastatic ...

Last Updated: 31 Dec 1969

Go To URL
Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma.
 

Author(s): Hangcheng Fu, Yidong Liu, Le Xu, Yuan Chang, Lin Zhou, Weijuan Zhang, Yuanfeng Yang, Jiejie Xu

Journal: Medicine (Baltimore). 2016 Apr;95(17):e3225.

 

Mucin-4 (MUC4), a member of membrane-bound mucins, has been reported to exert a large variety of distinctive roles in tumorigenesis of different cancers. MUC4 is aberrantly expressed in clear-cell renal cell carcinoma (ccRCC) but its prognostic value is still unveiled. This study ...

Last Updated: 31 Dec 1969

Go To URL
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
 

Author(s): R J Motzer, A Alyasova, D Ye, A Karpenko, H Li, B Alekseev, L Xie, G Kurteva, R Kowalyszyn, O Karyakin, Y Neron, T Cosgriff, L Collins, T Brechenmacher, C Lin, L Morgan, L Yang

Journal: Ann. Oncol.. 2016 Mar;27(3):441-8.

 

RECORD-1 demonstrated clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) previously treated with sunitinib, sorafenib, or both; prior treatment with cytokines, bevacizumab, and chemotherapy was also permitted. RECORD-4 prospectively assessed everolimus ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Renal cell carcinoma 4" returned 0 free, full-text review articles on human participants.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Cardiovascular Effects of Sunitinib Therapy (CREST)
 

Status: Recruiting

Condition Summary: Renal Cell Carcinoma 4

 

Last Updated: 6 Dec 2016

Go to URL
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
 

Status: Recruiting

Condition Summary: Clear Cell Renal Cell Carcinoma

 

Last Updated: 29 Sep 2017

Go to URL
Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma
 

Status: Recruiting

Condition Summary: Clear Cell Renal Cell Carcinoma

 

Last Updated: 24 Jul 2017

Go to URL